Abstract
Myelofibrosis(MF)is a myeloproliferative neoplasms(MPN),usually accomplies with thrombocytopenia,severely impacts the life quality of patients and presents a risk for leukemic transformation.Pacritinib is a kind of Janus activated kinase 2(JAK2)and Fms-like tyrosine kinase 3(FLT3)inhibitor.U.S.FDA has granted accelerated approval for pacritinib capsules(Vonjo),on Feb 28,2022,in the treatment of adult patients with the platelet(blood clotting cells)levels below 50000·μL^(-1)who have a rare form of bone marrow disorder known as intermediate or high-risk primary and secondary myelofibrosis.The oral dose of 200 mg twice daily showed good clinical efficacy and manageable safety.In this paper,the mechanism of action,pharmacodynamics,pharmacokinetics,safety,and clinical efficacy of daridorexant are reviewed.
| Translated title of the contribution | Pacritinib:a new Janus activated kinase 2/Fms-like tyrosine kinase 3 inhibitor for the treatment of myelofibrosis |
|---|---|
| Original language | Chinese |
| Pages (from-to) | 994-999 |
| Number of pages | 6 |
| Journal | Chinese Journal of New Drugs |
| Volume | 32 |
| Issue number | 10 |
| State | Published - 1 May 2023 |
Indexed by
- Scopus
- CSCD
Fingerprint
Dive into the research topics of 'Pacritinib:a new Janus activated kinase 2/Fms-like tyrosine kinase 3 inhibitor for the treatment of myelofibrosis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver